The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The global conjugate vaccine market is set for substantial growth, projecting an increase from $14.69 billion in 2022 to $16.77 billion in 2023, with a robust Compound Annual Growth Rate (CAGR) of 14.2%. Peering into the future, the forecast anticipates a market size of $27.22 billion in 2027, maintaining a significant CAGR of 12.9%. What fuels this growth? The rise in the use of conjugate vaccines for adults takes center stage, bolstering the market’s expansion.

Fortifying Adult Immunization

• Bacterial Defense: Conjugate vaccines are crafted to elicit a robust immune response against bacterial capsular polysaccharides. This enhancement of the body’s defense mechanism proves crucial in countering bacterial infections.
• Reducing Risks: The use of conjugate vaccines in adults serves a dual purpose: reducing the risk of severe illness and complications while curbing the transmission of bacterial diseases. This is achieved by stimulating a strong immune response that acts as a shield against potential infections.
• Global Uptake: Notable examples include Australia, where historical influenza vaccine coverage for the 15 – < 50 years age group rose from 22.8% in 2021 to 29.5% at the end of 2022, as reported by the National Centre for Immunization Research and Surveillance.

Market Leaders Charting the Course
Major players play a pivotal role in steering the trajectory of the conjugate vaccine market, contributing to its growth and shaping its landscape.

• Major Players: Sanofi S.A, Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., and Bio-Med Pvt. Ltd.

The Era of Innovation
Innovation is emerging as a dominant trend in the dynamic landscape of the conjugate vaccine market. Companies are actively investing in developing novel conjugate vaccines, fortifying their market positions.

• Prevnar 20: Pfizer Inc., in June 2022, unveiled Prevnar 20, a pneumococcal 20-valent conjugate vaccine, launched in Canada. This innovative vaccine aims to prevent pneumonia and invasive pneumococcal infections in adults aged 18 and older. Prevnar 20 covers 13 serotypes from PREVNAR 13 and introduces conjugates for seven additional serotypes linked to severe pneumococcal diseases.

Market Segmentation: A Comprehensive View

• By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
• By Pathogen: Bacterial, Viral
• By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid
• By Patient: Pediatric, Adults
• By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Regional Dynamics

• North America Leading: As of 2022, North America claims the lion’s share in the global conjugate vaccine market. However, looking ahead, Asia-Pacific is poised to emerge as the fastest-growing region, indicating the global reach of this evolving market.

View More On The Conjugate Vaccine Market Report 2023 – https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

Request A Sample Of The Global Conjugate Vaccine Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=10850&type=smp

The Conjugate Vaccine Global Market Report 2023  provides an in-depth analysis on the conjugate vaccine market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the conjugate vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –
H1N1 Vaccine Global Market Report 2023
DTP Vaccines Global Market Report 2023
Meningococcal Vaccines Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model